Fig. S5
Inhibition of Pol III function leads to HSPC defects. (A) qRT-PCR demonstrated that, compared to DMSO treated embryos, products of Pol III (pre-tRNAIle, pre-tRNALeu, 5S rRNA, 7SL RNA) were all significantly decreased in embryos at 5 dpf treated with ML-60218 (Pol III inhibitor). 18S rRNA was used as internal control (mean±SD, ***P < 0.001). (B) WISH result showed the expression pattern of vascular marker flk1, HSPC marker cmyb, differentiated hematopoietic cell lineage markers (gata1, pu.1 and rag1) and thymus epithelial cell marker foxn1 in DMSO or ML-60218 treated embryos. (C) qRT-PCR result revealed that cmyb, gata1, and pu.1 were decreased in embryos treated with ML-60218. β-actin was used as internal control (mean±SD, **P < 0.01, ***P < 0.001). Note that arrowheads in (B) mark the CHT or the thymus.